APA (7th ed.) Citation

V, J., K, S., J, S., Z, B., M, M., D, R., & M, C. (2022). Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma. Dose-response : a publication of International Hormesis Society, 20(3), 15593258221117354. https://doi.org/10.1177/15593258221117354

Chicago Style (17th ed.) Citation

V, Jokic, Savic-Vujovic K, Spasic J, Bukumiric Z, Marinkovic M, Radosavljevic D, and Cavic M. "Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma." Dose-response : A Publication of International Hormesis Society 20, no. 3 (2022): 15593258221117354. https://doi.org/10.1177/15593258221117354.

MLA (9th ed.) Citation

V, Jokic, et al. "Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma." Dose-response : A Publication of International Hormesis Society, vol. 20, no. 3, 2022, p. 15593258221117354, https://doi.org/10.1177/15593258221117354.